RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
JAMA : the journal of the American Medical Association JAMA, 329(1), 39-51. American Medical Association Journal of the American Medical Association Journal of the American Medical Association, 2023, 329 (1), pp.39-51. ⟨10.1001/jama.2022.23257⟩ Jama : Journal of the American Medical Association, 329, 1, pp. 39-51 Higgins, A M, Berry, L R, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, P R, Al-Beidh, F, Annane, D, Arabi, Y M, Beane, A, Van Bentum-Puijk, W, Bhimani, Z, Bonten, M J M, Bradbury, C A, Brunkhorst, F M, Burrell, A, Buzgau, A, Buxton, M, Charles, W N, Cove, M, Detry, M A, Estcourt, L J, Fagbodun, E O, Fitzgerald, M, Girard, T D, Goligher, E C, Goossens, H, Haniffa, R, Hills, T, Horvat, C M, Huang, D T, Ichihara, N, Lamontagne, F, Marshall, J C, McAuley, D F, McGlothlin, A, McGuinness, S P, McVerry, B J, Neal, M D, Nichol, A D, Parke, R L, Parker, J C, Parry-Billings, K, Peters, S E C, Reyes, L F, Rowan, K M, Saito, H, Santos, M S, Saunders, C T & Serpa-Neto, A 2023, ' Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial ', JAMA, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Bradbury, C A & Higgins, A M 2023, ' Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial ', JAMA-Journal of the American Medical Association, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Jama : Journal of the American Medical Association, 329, 39-51 JAMA
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
2022, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, pp. 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Liew, F, Talwar, S, Cross, A, Willett, B J, Scott, S, Logan, N, Siggins, M K, Swieboda, D, Sidhu, J K, Efstathiou, C, Moore, S C, Davis, C, Mohamed, N, Nunag, J, King, C, Thompson, A A R, Rowland-Jones, S L, Docherty, A B, Chalmers, J D, Ho, L-P, Horsley, A, Raman, B, Poinasamy, K, Marks, M, Kon, O M, Howard, L, Wootton, D G, Dunachie, S, Quint, J K, Evans, R A, Wain, L V, Fontanella, S, de Silva, T I, Ho, A, Harrison, E, Baillie, J K, Semple, M G, Brightling, C, Thwaites, R S, Turtle, L, Openshaw, P J M, ISARIC4C Investigators, Armour, C, Carson, G, Busby, J, Connolly, B, Cooper, J, Drain, S, Grieve, D, Hart, N, Harvey, M, Heaney, L G, Hughes, J, Jones, M G, Magee, N, McArdle, A, McGarvey, L, Mills, C, Mitchell, J, Peto, T, Powell, N, Rowland, M, Sharma, M & Siddiqui, S 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Horsley, A, Dark, P, Felton, T, et al, ISARIC4C Investigators & PHOSP-COVID Collaborative Group 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402